BioCentury
ARTICLE | Emerging Company Profile

Algodign: From Russia with data

March 22, 2004 8:00 AM UTC

When he co-founded Protein Design Labs Inc., Cary Queen brought to the company the idea of using computer modeling to improve proteins - antibodies in the case of PDLI. Now, as chairman of Algodign Inc., he's expanding the idea to small molecules. Although not the first company to use computer-based drug design, Algodign believes its software offers advantages compared to competing technologies, because it does not require co-crystal structures of compounds bound to proteins. In addition, the software generates compounds that can be manufactured readily.

Queen essentially runs Algodign on his own nickel - he is funding the company with proceeds from the sale of his stock in PDLI (Fremont, Calif.). As a result, Queen is determined to maintain a lean organization and accordingly has chosen Moscow as the hub of Algodign's research efforts. ...